PharVision Advisers’s Quanterix QTRX Stock Holding History

PharVision Advisers’s Portfolio QTRX Stock Details QTRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-36,144	Closed	-$196K	–	946
2025 Q3	$196K	Buy	+36,144	New	+$192K	0.11%	523

Other funds holding QTRX

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's QTRX Position: Q4 2025 in Review

PharVision Advisers sold out of Quanterix (QTRX) in Q4 2025, closing a stake of 36,144 shares — an estimated $196K sold.

PharVision Advisers first reported a position in QTRX in Q3 2025 and held it in 1 quarter. The position peaked at $196K in Q3 2025. 134 funds tracked by Wall St. Rank hold QTRX as of Q4 2025.

PharVision Advisers reported no remaining Quanterix position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 36,144 Quanterix shares in Q4 2025, an estimated $196K.
PharVision Advisers first reported a position in Quanterix in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Quanterix position peaked at $196K in Q3 2025.
134 funds tracked by Wall St. Rank held Quanterix as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.